BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
BioAtla (BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Fourth Quarter and Full-Year 2024 financial results announcement for March 27, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide business updates. Interested parties can access the call through domestic (800-245-3047) or international (203-518-9765) dial-in numbers using the Conference ID: BIOATLA.
BioAtla (BCAB), un'azienda biotecnologica globale in fase clinica specializzata in terapie anticorpali biologiche attive condizionalmente (CAB) per il trattamento dei tumori solidi, ha programmato l'annuncio dei risultati finanziari del Quarto Trimestre e dell'Anno Fiscale 2024 per il 27 marzo 2025.
L'azienda organizzerà una conferenza telefonica e una diretta web alle 16:30 ET per discutere le performance finanziarie e fornire aggiornamenti aziendali. Le parti interessate possono accedere alla chiamata tramite numeri di telefono nazionali (800-245-3047) o internazionali (203-518-9765) utilizzando l'ID Conferenza: BIOATLA.
BioAtla (BCAB), una empresa biotecnológica global en etapa clínica especializada en terapias de anticuerpos biológicos activados condicionalmente (CAB) para el tratamiento de tumores sólidos, ha programado el anuncio de sus resultados financieros del Cuarto Trimestre y del Año Fiscal 2024 para el 27 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo a las 4:30 p.m. ET para discutir el rendimiento financiero y proporcionar actualizaciones comerciales. Las partes interesadas pueden acceder a la llamada a través de números de marcación nacionales (800-245-3047) o internacionales (203-518-9765) utilizando el ID de Conferencia: BIOATLA.
BioAtla (BCAB)는 고형 종양 치료를 위한 조건부 활성 생물학적(CAB) 항체 치료제에 특화된 글로벌 임상 단계 생명공학 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일로 예정하고 있습니다.
회사는 오후 4시 30분 ET에 재무 성과를 논의하고 비즈니스 업데이트를 제공하는 전화 회의 및 웹캐스트를 개최할 예정입니다. 관심 있는 분들은 국내(800-245-3047) 또는 국제(203-518-9765) 전화번호를 통해 회의 ID: BIOATLA를 사용하여 전화를 이용할 수 있습니다.
BioAtla (BCAB), une entreprise biopharmaceutique mondiale en phase clinique spécialisée dans les thérapies anticorporelles biologiques activées conditionnellement (CAB) pour le traitement des tumeurs solides, a prévu l'annonce de ses résultats financiers pour le quatrième trimestre et l'année 2024 le 27 mars 2025.
L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET pour discuter de la performance financière et fournir des mises à jour commerciales. Les parties intéressées peuvent accéder à l'appel via des numéros de téléphone nationaux (800-245-3047) ou internationaux (203-518-9765) en utilisant l'ID de conférence : BIOATLA.
BioAtla (BCAB), ein globales biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf bedingt aktive biologische (CAB) Antikörpertherapeutika zur Behandlung solider Tumoren spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das 4. Quartal und das Gesamtjahr 2024 für den 27. März 2025 angesetzt.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die finanzielle Leistung zu besprechen und Unternehmensupdates bereitzustellen. Interessierte Parteien können über nationale (800-245-3047) oder internationale (203-518-9765) Einwahlnummern mit der Konferenz-ID: BIOATLA auf die Konferenz zugreifen.
- None.
- None.
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights.
Conference Call and Webcast Information
Date: Thursday, March 27, 2025
Time: 4:30 p.m. ET
Webcast Link: BioAtla Fourth Quarter and Full-Year 2024 Earnings Conference Call
Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)
Conference ID: BIOATLA
The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The Company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When will BioAtla (BCAB) release its Q4 and full-year 2024 earnings?
How can investors access BioAtla's (BCAB) Q4 2024 earnings call?
Where can I find BioAtla's (BCAB) Q4 2024 earnings press release?
What is BioAtla's (BCAB) main business focus?
